Cannabis Science Inc (OTCMKTS:CBIS) has been a source of some fun facts over the years. Here’s a good one: without any reverse splits, the stock would be trading on 19.37 trillion shares at $0.000000138/share (ie, you would be rooting for a quick 7,400% rally to get back to that penny level). If you were an early investor here, you didn’t fare well.
But times have changed. The company is a real player in the medical marijuana space at a time when cannabis is finally likely entering its heyday. With November votes quickly approaching in which we will see four new states go to the ballot boxes with new potential medical legalization votes (Arkansas, Florida, Montana, and North Dakota), we would expect CBIS to get a lot of attention. But so far, over the past few weeks, the stock’s recent average trading volume is actually dropping (-20%), which is odd and looks like a cautionary signal in this type of catalyst-driven scenario. But let’s take a closer look.
Cannabis Science Inc (OTCMKTS:CBIS) frames itself as a compay that develops, produces, and commercializes phyto cannabinoid-based pharmaceutical products primarily in the United States.
The company is involved in developing medicines for autism, blood pressure, cancer and cancer side effects, as well as for other illnesses comprising for general health maintenance. It also develops CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary cannabis-based therapy for neurological conditions.
In addition, the company offers an online video-based medical cannabis education system, including courses, such as medical cannabis law, medical marijuana, cooking, horticulture, and bud tending; and manufactures and distributes specialty horse and pet grooming and topical applications.
It has a license agreement with Apothecary Genetics Investments LLC to produce various brand formulations for California medical cannabis market.
The company also has collaboration with IGXBio, Inc. to develop GenePro, a DNA-based immunotherapeutic drug. Cannabis Science, Inc. is based in Colorado Springs, Colorado. Cannabis Science, Inc. is a subsidiary of Weedmaps Media, Inc.
Find out when CBIS reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As for how the Company frames itself at this point, here’s the tag on pressers:
“CBIS takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.”
I can’t really tell you whether or not the ships mentioned in the above paragraph are going to set sail and catch wind. However, I am perfectly happy to let the market be my guide at this point.
Now commanding a market cap of $27.2M, CBIS has very little cash on the books, in a pool of total assets exceeding $2M, which stands against a mountain of liabilities over $4.8M.
What everyone knows is this: the cannabis market is a highly catalyzed scenario right now. There are dozens of other cannabis-related stocks ripping higher in the past two weeks. CBIS is flat and seeing declining volume. Most of the others have some real revenue growth to speak of, and a set of C-level execs with the chops to run a fast growth machine. The big point is, whether you’re a bull or a bear on CBIS right now, you can probably throw a dart at a weed website and hit something that will rally into November. If that’s the theme you are playing, there are probably better places to do it than CBIS. If that situation changes, you can bet we will be there with an update. To get the full story on CBIS subscribe below to Oracle Dispatch right now.